CAC
MIST icon

Cowen and Company’s Milestone Pharmaceuticals MIST Stock Holding History

Cowen and Company’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,700
Closed -$21K – 651
2021
Q1 		$21K Buy
+8,700
New +$63.7K ﹤0.01% 450
2020
Q4 		– Sell
-27,600
Closed -$47K – 484
2020
Q3 		$47K Buy
+27,600
New +$198K 0.01% 305

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's MIST Position: Q4 2022 in Review

Cowen and Company sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 14,000 shares — an estimated $20K sold.

Cowen and Company first reported a position in MIST in Q3 2020 and held it in 3 quarters. The position peaked at $88K in Q3 2020. 56 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

  • Cowen and Company reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 14,000 Milestone Pharmaceuticals shares in Q4 2022, an estimated $20K.
  • Cowen and Company first reported a position in Milestone Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Cowen and Company's Milestone Pharmaceuticals position peaked at $88K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.